Rapid Selection of Active Circulating Tumor Cells Using Combined Electrical and Optical Detection in a “Lab on Chip” Platform

A Microfluidic Platform for On-Chip Analysis of Circulating Tumor Cells

10.1115/fedsm2021-65766 ◽

2021 ◽

Author(s):

Jeff Darabi ◽

Joseph Schober

Keyword(s):

Cancer Cells ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Whole Blood ◽

Peripheral Blood ◽

Automated Image Analysis ◽

Rare Cancer ◽

On Chip ◽

Chip Analysis ◽

Selection Of

Abstract Studies have shown that primary tumor sites begin shedding cancerous cells into peripheral blood at early stages of cancer, and the presence and frequency of circulating tumor cells (CTCs) in blood is directly proportional to disease progression. The challenge is that the concentration of the CTCs in peripheral blood may be extremely low. In the past few years, several microfluidic-based concepts have been investigated to isolate CTCs from whole blood. However, these devices are generally hampered by complex fabrication processes and very low volumetric throughputs, which may not be practical for rapid clinical applications. This paper presents a high-performance yet simple magnetophoretic microfluidic chip for the enrichment and on-chip analysis of rare CTCs from blood. Microscopic and flow cytometric assays developed for selection of cancer cell lines, selection of monoclonal antibodies, and optimization of bead coupling are discussed. Additionally, on-chip characterization of rare cancer cells using high resolution immunofluorescence microscopy and modeling results for prediction of CTC capture length are presented. The device has the ability to interface directly with on-chip pre and post processing modules such as mixing, incubation, and automated image analysis systems. These features will enable us to isolate rare cancer cells from whole blood and detect them on the chip with subcellular resolution.

Download Full-text

Lab-on-chip for the Isolation and Characterization of Circulating Tumor Cells

2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society ◽

10.1109/iembs.2007.4353833 ◽

2007 ◽

Author(s):

Tina Roeser ◽

Marion Ritzi ◽

Klaus S. Drese ◽

Wim Laureyn ◽

Chengxun Liu ◽

...

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Lab On Chip ◽

Isolation And Characterization ◽

On Chip

Download Full-text

Aptamer-Based Lab-on-Chip for Cancer Cell Isolation and Detection

ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology ◽

10.1115/nemb2010-13195 ◽

2010 ◽

Author(s):

Yuan Wan ◽

Young-tae Kim ◽

Li Na ◽

Andrew D. Ellington ◽

Samir M. Iqbal

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Cancer Detection ◽

Early Cancer ◽

Growth Factor Receptor ◽

Lab On A Chip ◽

Early Cancer Detection ◽

Lab On Chip ◽

Epidermal Growth ◽

On Chip

The isolation and detection of circulating tumor cells (CTCs), when these are few in number or small in mass, can enable early cancer detection [1]. Currently, most research endeavors to isolate circulating tumor cells rely on antibodies and immunohistochemistry [2,3]. Aptamer are alternative molecules that have affinities and specificities that are comparable to those of antibodies [4,5], but these can be more readily adapted to many applications [6–9], including lab-on-a-chip devices. Here, we report use of a novel epidermal growth factor receptor (EGFR) aptamer biochip to identify and isolate cancer cells that overexpress EGFR. These results provide a solid basis for the development of diagnostic devices that can readily identify and isolate CTCs.

Download Full-text

Lab-on-chip platform for circulating tumor cells isolation

10.1117/12.2201127 ◽

2015 ◽

Author(s):

D. K. Maurya ◽

M. Fooladvand ◽

E. Gray ◽

M. Ziman ◽

K. Alameh

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Lab On Chip ◽

On Chip

Download Full-text

Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine

BioMed Research International ◽

10.1155/2017/7206307 ◽

2017 ◽

Vol 2017 ◽

pp. 1-9 ◽

Cited By ~ 3

Author(s):

Yoon Seok Suh ◽

Jae Young Joung ◽

Sung Han Kim ◽

Ho Kyung Seo ◽

Jinsoo Chung ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Liquid Biopsy ◽

Disease Status ◽

Minimal Invasive ◽

Future Directions ◽

Advantages And Disadvantages ◽

Potential Tool ◽

Selection Of

Prostate cancer (PC) is the second most common cancer in men and is the fifth leading cause of cancer-related deaths worldwide. Additionally, there is concern for overdiagnosis and overtreatment of PC. Thus, selection of an appropriate candidate for active surveillance as well as more accurate and less invasive tools for monitoring advanced PC is required. Circulating tumor cells (CTCs) have emerged as a liquid biopsy tool; there have been several reports on its role, technologies, and applications to various cancers, including PC. Liquid biopsy using CTCs has been gaining attention as a minimal invasive tool for investigation of biomarkers and for prognosis and assessment of response to therapies in patients with PC. Because of the lower invasiveness of liquid biopsy using CTCs, it can be performed more frequently; accordingly, personalized disease status can be successively determined at serial time points. CTC analysis enables detection of genomic alterations, which is drug-targetable, and it is a potential tool for monitoring response to therapeutic agents in patients with PC. This review focuses on the characteristics, technologies for analysis, and advantages and disadvantages of CTCs as a liquid biopsy tool and their application in PC. Finally, we propose future directions of CTCs.

Download Full-text